Abstract
Background Intranasal sprays must be delivered to the nasal cavity in sufficient volume, appropriate viscosity and droplet size and with a technique that allows optimal retention, maximizes absorption from the mucosa, and the potential for maximum therapeutic effect. The aim of this study was to evaluate nasal drug run-off after administration of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) with sequential administration of marketed AZE and FP nasal sprays in vitro.
Highlights
Intranasal sprays must be delivered to the nasal cavity in sufficient volume, appropriate viscosity and droplet size and with a technique that allows optimal retention, maximizes absorption from the mucosa, and the potential for maximum therapeutic effect
Three replicates of sequential sprays of AZE followed 1 min later by either branded or generic FP showed significant anterior nasal drip from the nostril and toward the back of the nasal cavity; AZE & branded FP: anterior spray area = 1.67 – 3.16 cm2; AZE & generic FP: anterior spray area: 0.68 – 1.83 cm2
The delivery of MP29-02* showed improved retention in the targeted areas compared to sequential administration of marketed intranasal monoproducts
Summary
Intranasal sprays must be delivered to the nasal cavity in sufficient volume, appropriate viscosity and droplet size and with a technique that allows optimal retention, maximizes absorption from the mucosa, and the potential for maximum therapeutic effect. The aim of this study was to evaluate nasal drug run-off after administration of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) with sequential administration of marketed AZE and FP nasal sprays in vitro
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.